NEW YORK (GenomeWeb) – KineMed and Camino Partnership today announced that they are partnering in an effort to acquire new drugs and targeted drug candidates for potential licensing opportunites.

According to the partners, KineMed plans to apply its proteomics technology in rapid proof-of-concept studies on up to six compounds over a three-year period and then out-license appropriate candidate drugs to pharmaceutical companies.

Initially, the effort will focus on drugs for oncology, neurodegenerative disorders, muscle wasting, and fibrosis diseases, the companies said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.